Briefings in BioinformaticsBioinformaticsPeer-reviewed journal article
Minimal information for Chemosensitivity assays (MICHA): A next-generation pipeline to enable the FAIRification of drug screening experiments
Ziaurrehman TanoliiD, Jehad AldahdoohiD, Farhan AlamiD, Yinyin WangiD, Umair SeemabiD, Maddalena FratelliiD, Petr Pavliš, Marián HajdúchiD, Florence BiétrixiD, Philip M. GribboniD, Andrea ZalianiiD, Matthew D. HalliD, Min SheniD, Kyle R. BrimacombeiD, Evgeny KulesskiyiD, Jani SaarelaiD, Krister WennerbergiD, Markus J. V. Vähä-KoskelaiD, Jing Ping TangiD
Abstract
Chemosensitivity assays are commonly used for preclinical drug discovery and clinical trial optimization. However, data from independent assays are often discordant, largely attributed to uncharacterized variation in the experimental materials and protocols. We report here the launching of MICHA (Minimal Information for Chemosensitivity Assays), accessed via https://micha-protocol.org. Distinguished from existing efforts that are often lacking support from data integration tools, MICHA can automatically extract publicly available information to facilitate the assay annotation including: 1) compounds, 2) samples, 3) reagents, and 4) data processing methods. For example, MICHA provides an integrative web server and database to obtain compound annotation including chemical structures, targets, and disease indications. In addition, the annotation of cell line samples, assay protocols and literature references can be greatly eased by retrieving manually curated catalogues. Once the annotation is complete, MICHA can export a report that conforms to the FAIR principle (Findable, Accessible, Interoperable and Reusable) of drug screening studies. To consolidate the utility of MICHA, we provide FAIRified protocols from five major cancer drug screening studies, as well as six recently conducted COVID-19 studies. With the MICHA webserver and database, we envisage a wider adoption of a community-driven effort to improve the open access of drug sensitivity assays.
- Citations
- 16
- FWCI
- 2.94
- Field percentile
- top 8%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies
Petr Smirnov, Victor Kofia, … Benjamin Haibe‐Kains·Nucleic Acids ResearchPeer-reviewed·Sep 27, 2017
- From Library to Landscape: Integrative Annotation Workflows for Compound Libraries in Drug Repurposing
Jeanette Reinshagen, Brinton A. Seashore-Ludlow, … Flavio Ballante·DatabasePeer-reviewed·Jan 1, 2025
- DrugComb - an integrative cancer drug combination data portal
B. Zagidullin, J. Aldahdooh, … J. Tang·bioRxiv·Feb 25, 2019
- Database for drug metabolism and comparisons, NICEdrug.ch, aids discovery and design
H. MohammadiPeyhani, A. Chiappino-Pepe, … V. Hatzimanikatis·bioRxiv·May 28, 2020
- Microscale assay to evaluate the minimum inhibitory concentration of purified compounds with limited sample volume
Shashank Kashyap, Sumit Biswas·bioRxiv·Jul 8, 2026
- Establishing the foundations for a data-centric AI approach for virtual drug screening through a systematic assessment of the properties of chemical data
A. Chong, S.-X. Phua, … W. W. B. Goh·bioRxiv·Mar 28, 2024